Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1111C IFN-alpha + zidovudine vs watchful waiting in indolent ATL
jRCTs031180169Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2013
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of interferon alfa and zidovudine in adult T-cell leukemia-lymphoma (ATLL) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Event-free survival. Started Nov 2013; status: completed.
02
Drugs
interferon alfazidovudine
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCTs031180169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180169.